The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 07, 2018

Filed:

Jun. 21, 2016
Applicant:

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Inventors:

Frederic Jaisser, Paris, FR;

Nicolette Farman, Paris, FR;

Yannis Sainte-Marie, Toulouse, FR;

Celine Latouche, Melbourne VIC, AU;

Marja Steenman, Nantes, FR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); G01N 33/68 (2006.01); C12Q 1/6883 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/04 (2013.01); G01N 2800/042 (2013.01); G01N 2800/044 (2013.01); G01N 2800/32 (2013.01); G01N 2800/321 (2013.01); G01N 2800/325 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.


Find Patent Forward Citations

Loading…